Literature DB >> 25316821

In vivo quantification of hypoxic and metabolic status of NSCLC tumors using [18F]HX4 and [18F]FDG-PET/CT imaging.

Catharina M L Zegers1, Wouter van Elmpt2, Bart Reymen2, Aniek J G Even2, Esther G C Troost2, Michel C Ollers2, Frank J P Hoebers2, Ruud M A Houben2, Jonas Eriksson3, Albert D Windhorst3, Felix M Mottaghy4, Dirk De Ruysscher5, Philippe Lambin2.   

Abstract

PURPOSE: Increased tumor metabolism and hypoxia are related to poor prognosis in solid tumors, including non-small cell lung cancer (NSCLC). PET imaging is a noninvasive technique that is frequently used to visualize and quantify tumor metabolism and hypoxia. The aim of this study was to perform an extensive comparison of tumor metabolism using 2[(18)F]fluoro-2-deoxy-d-glucose (FDG)-PET and hypoxia using HX4-PET imaging. EXPERIMENTAL
DESIGN: FDG- and HX4-PET/CT images of 25 patients with NSCLC were coregistered. At a global tumor level, HX4 and FDG parameters were extracted from the gross tumor volume (GTV). The HX4 high-fraction (HX4-HF) and HX4 high-volume (HX4-HV) were defined using a tumor-to-blood ratio > 1.4. For FDG high-fraction (FDG-HF) and FDG high-volume (FDG-HV), a standardized uptake value (SUV) > 50% of SUVmax was used. We evaluated the spatial correlation between HX4 and FDG uptake within the tumor, to quantify the (mis)match between volumes with a high FDG and high HX4 uptake.
RESULTS: At a tumor level, significant correlations were observed between FDG and HX4 parameters. For the primary GTV, the HX4-HF was three times smaller compared with the FDG-HF. In 53% of the primary lesions, less than 1 cm(3) of the HX4-HV was outside the FDG-HV; for 37%, this volume was 1.9 to 12 cm(3). Remarkably, a distinct uptake pattern was observed in 11%, with large hypoxic volumes localized outside the FDG-HV.
CONCLUSION: Hypoxic tumor volumes are smaller than metabolic active volumes. Approximately half of the lesions showed a good spatial correlation between the PET tracers. In the other cases, a (partial) mismatch was observed. The addition of HX4-PET imaging has the potential to individualize patient treatment. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25316821      PMCID: PMC5228298          DOI: 10.1158/1078-0432.CCR-14-1524

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  47 in total

1.  Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.

Authors:  Yoko Satoh; Hiroshi Onishi; Atsushi Nambu; Tsutomu Araki
Journal:  Radiology       Date:  2013-10-28       Impact factor: 11.105

2.  Intra-patient variability of tumor volume and tumor motion during conventionally fractionated radiotherapy for locally advanced non-small-cell lung cancer: a prospective clinical study.

Authors:  Geert Bosmans; Angela van Baardwijk; André Dekker; Michel Ollers; Liesbeth Boersma; André Minken; Philippe Lambin; Dirk De Ruysscher
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-11-01       Impact factor: 7.038

3.  PET imaging of hypoxia using [18F]HX4: a phase I trial.

Authors:  Judith van Loon; Marco H M Janssen; Michel Ollers; Hugo J W L Aerts; Ludwig Dubois; Monique Hochstenbag; Anne-Marie C Dingemans; Roy Lalisang; Boudewijn Brans; Bert Windhorst; Guus A van Dongen; Hartmuth Kolb; James Zhang; Dirk De Ruysscher; Philippe Lambin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-04-06       Impact factor: 9.236

4.  Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer.

Authors:  Michael Milosevic; Padraig Warde; Cynthia Ménard; Peter Chung; Ants Toi; Adrian Ishkanian; Michael McLean; Melania Pintilie; Jenna Sykes; Mary Gospodarowicz; Charles Catton; Richard P Hill; Robert Bristow
Journal:  Clin Cancer Res       Date:  2012-03-31       Impact factor: 12.531

5.  The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer.

Authors:  Wouter van Elmpt; Dirk De Ruysscher; Anke van der Salm; Annemarie Lakeman; Judith van der Stoep; Daisy Emans; Eugène Damen; Michel Öllers; Jan-Jakob Sonke; José Belderbos
Journal:  Radiother Oncol       Date:  2012-04-06       Impact factor: 6.280

6.  Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy.

Authors:  Susanne-Martina Eschmann; Frank Paulsen; Matthias Reimold; Helmut Dittmann; Stefan Welz; Gerald Reischl; Hans-Juergen Machulla; Roland Bares
Journal:  J Nucl Med       Date:  2005-02       Impact factor: 10.057

7.  High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.

Authors:  Shozo Okamoto; Tohru Shiga; Koichi Yasuda; Yoichi M Ito; Keiichi Magota; Katsuhiko Kasai; Yuji Kuge; Hiroki Shirato; Nagara Tamaki
Journal:  J Nucl Med       Date:  2013-01-15       Impact factor: 10.057

8.  The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer.

Authors:  Angela van Baardwijk; Christophe Dooms; Robert Jan van Suylen; Erik Verbeken; Monique Hochstenbag; Cary Dehing-Oberije; Dennis Rupa; Silvia Pastorekova; Sigrid Stroobants; Ulrich Buell; Philippe Lambin; Johan Vansteenkiste; Dirk De Ruysscher
Journal:  Eur J Cancer       Date:  2007-05-23       Impact factor: 9.162

9.  PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients.

Authors:  Vikram R Bollineni; Gerald S M A Kerner; Jan Pruim; Roel J H M Steenbakkers; Erwin M Wiegman; Michel J B Koole; Eleonore H de Groot; Antoon T M Willemsen; Gert Luurtsema; Joachim Widder; Harry J M Groen; Johannes A Langendijk
Journal:  J Nucl Med       Date:  2013-06-10       Impact factor: 10.057

10.  Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer.

Authors:  Talakad Goolaiah Lohith; Takashi Kudo; Yoshiki Demura; Yukihiro Umeda; Yasushi Kiyono; Yasuhisa Fujibayashi; Hidehiko Okazawa
Journal:  J Nucl Med       Date:  2009-11-12       Impact factor: 10.057

View more
  25 in total

1.  Prospective Evaluation of a Tumor Control Probability Model Based on Dynamic 18F-FMISO PET for Head and Neck Cancer Radiotherapy.

Authors:  Daniela Thorwarth; Stefan Welz; David Mönnich; Christina Pfannenberg; Konstantin Nikolaou; Matthias Reimold; Christian La Fougère; Gerald Reischl; Paul-Stefan Mauz; Frank Paulsen; Markus Alber; Claus Belka; Daniel Zips
Journal:  J Nucl Med       Date:  2019-05-10       Impact factor: 10.057

Review 2.  Molecular imaging of hypoxia in non-small-cell lung cancer.

Authors:  Connie Yip; Philip J Blower; Vicky Goh; David B Landau; Gary J R Cook
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-21       Impact factor: 9.236

Review 3.  Validation of functional imaging as a biomarker for radiation treatment response.

Authors:  C Jentsch; B Beuthien-Baumann; E G C Troost; G Shakirin
Journal:  Br J Radiol       Date:  2015-05-29       Impact factor: 3.039

Review 4.  Dual-Mode Tumor Imaging Using Probes That Are Responsive to Hypoxia-Induced Pathological Conditions.

Authors:  S A Amali S Subasinghe; Robia G Pautler; Md Abul Hassan Samee; Jason T Yustein; Matthew J Allen
Journal:  Biosensors (Basel)       Date:  2022-06-30

5.  Robust Intratumor Partitioning to Identify High-Risk Subregions in Lung Cancer: A Pilot Study.

Authors:  Jia Wu; Michael F Gensheimer; Xinzhe Dong; Daniel L Rubin; Sandy Napel; Maximilian Diehn; Billy W Loo; Ruijiang Li
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-03-24       Impact factor: 7.038

6.  Repeatability of hypoxia PET imaging using [¹⁸F]HX4 in lung and head and neck cancer patients: a prospective multicenter trial.

Authors:  Catharina M L Zegers; Wouter van Elmpt; Katrin Szardenings; Hartmuth Kolb; Alan Waxman; Rathan M Subramaniam; Dae Hyuk Moon; Jacqueline C Brunetti; Shyam M Srinivas; Philippe Lambin; David Chien
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-02       Impact factor: 9.236

7.  Analysis of pairwise correlations in multi-parametric PET/MR data for biological tumor characterization and treatment individualization strategies.

Authors:  Sara Leibfarth; Urban Simoncic; David Mönnich; Stefan Welz; Holger Schmidt; Nina Schwenzer; Daniel Zips; Daniela Thorwarth
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-02-13       Impact factor: 9.236

8.  Nucleophosmin 1 overexpression correlates with 18F-FDG PET/CT metabolic parameters and improves diagnostic accuracy in patients with lung adenocarcinoma.

Authors:  Lu-Meng Zhou; Ling-Ling Yuan; Yan Gao; Xu-Sheng Liu; Qin Dai; Jian-Wei Yang; Zhi-Jun Pei
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-08-27       Impact factor: 9.236

Review 9.  Value of PET imaging for radiation therapy.

Authors:  Constantin Lapa; Ursula Nestle; Nathalie L Albert; Christian Baues; Ambros Beer; Andreas Buck; Volker Budach; Rebecca Bütof; Stephanie E Combs; Thorsten Derlin; Matthias Eiber; Wolfgang P Fendler; Christian Furth; Cihan Gani; Eleni Gkika; Anca-L Grosu; Christoph Henkenberens; Harun Ilhan; Steffen Löck; Simone Marnitz-Schulze; Matthias Miederer; Michael Mix; Nils H Nicolay; Maximilian Niyazi; Christoph Pöttgen; Claus M Rödel; Imke Schatka; Sarah M Schwarzenboeck; Andrei S Todica; Wolfgang Weber; Simone Wegen; Thomas Wiegel; Constantinos Zamboglou; Daniel Zips; Klaus Zöphel; Sebastian Zschaeck; Daniela Thorwarth; Esther G C Troost
Journal:  Strahlenther Onkol       Date:  2021-07-14       Impact factor: 3.621

10.  High Resolution Ultrasound and Photoacoustic Imaging of Orthotopic Lung Cancer in Mice: New Perspectives for Onco-Pharmacology.

Authors:  Florian Raes; Julien Sobilo; Marilyne Le Mée; Stéphanie Rétif; Sharuja Natkunarajah; Stéphanie Lerondel; Alain Le Pape
Journal:  PLoS One       Date:  2016-04-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.